Literature DB >> 12536359

Hyperprolactinemia: etiology, diagnosis, and management.

Peak Mann Mah1, Jonathan Webster.   

Abstract

Hyperprolactinemia is the most common endocrine disorder of the hypothalamic-pituitary axis. A prolactinoma is the most common cause of chronic hyperprolactinemia once pregnancy, primary hypothyroidism, and drugs that elevate serum prolactin levels have been excluded. Patients can present with hypogonadism, infertility, galactorrhea, osteopenia, and mass effects of the tumor. When hyperprolactinemia is confirmed, a cause for the disorder needs to be sought. This involves a careful history and examination, followed by laboratory tests and diagnostic imaging of the sella turcica. The goals of treatment are to normalize prolactin levels, restore gonadal function, and reduce the effects of chronic hyperprolactinemia. Dopamine agonists are the treatment of choice for the majority of patients. Transsphenoidal surgery is usually reserved for patients who are intolerant of or resistant to dopamine agonists or when hyperprolactinemia is caused by non-prolactin-secreting tumors compressing the pituitary stalk. Cabergoline has been shown to be more effective and better tolerated than bromocriptine. However, there are more data on the safety of the latter drug during pregnancy and bromocriptine, therefore, remains the treatment of choice in hyperprolactinemic women wishing to conceive.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12536359     DOI: 10.1055/s-2002-36709

Source DB:  PubMed          Journal:  Semin Reprod Med        ISSN: 1526-4564            Impact factor:   1.303


  22 in total

1.  Molecular basis for catecholaminergic neuron diversity.

Authors:  Jan Grimm; Anne Mueller; Franz Hefti; Arnon Rosenthal
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-07       Impact factor: 11.205

2.  Retinal layers in prolactinoma patients: a spectral-domain optical coherence tomography study.

Authors:  Berna Evranos Ogmen; Nagihan Ugurlu; Sevgül Faki; Sefika Burcak Polat; Reyhan Ersoy; Bekir Cakir
Journal:  Int Ophthalmol       Date:  2021-01-22       Impact factor: 2.031

Review 3.  Effects of cabergoline on pregnancy and embryo-fetal development: retrospective study on 103 pregnancies and a review of the literature.

Authors:  Graciela Stalldecker; María Susana Mallea-Gil; Mirtha Guitelman; Analía Alfieri; María Carolina Ballarino; Laura Boero; Alberto Chervin; Karina Danilowicz; Sabrina Diez; Patricia Fainstein-Day; Natalia García-Basavilbaso; Mariela Glerean; Viviana Gollan; Débora Katz; Mónica Graciela Loto; Marcos Manavela; Amelia Susana Rogozinski; Marisa Servidio; Nicolás Marcelo Vitale
Journal:  Pituitary       Date:  2010-12       Impact factor: 4.107

4.  Pilot study on sex hormone levels and fertility in women with malignant gliomas.

Authors:  Matthias Preusser; Stefanie Seywald; Katarzyna Elandt; Christine Kurz; Andrea Rottenfusser; Karin Dieckmann; Gabriele Altorjai; Christoph C Zielinski; Christine Marosi
Journal:  J Neurooncol       Date:  2011-11-20       Impact factor: 4.130

5.  Suberoylanilide hydroxamic acid (SAHA) induces growth arrest and apoptosis in pituitary adenoma cells.

Authors:  S R Sangeetha; Nagendra Singh; John R Vender; Krishnan M Dhandapani
Journal:  Endocrine       Date:  2009-03-17       Impact factor: 3.633

6.  Hyperprolactinemia with normal serum prolactin: Its clinical significance.

Authors:  Manika Agarwal; Ananya Das; Santa A Singh
Journal:  J Hum Reprod Sci       Date:  2010-05

7.  Primary hypothyroidism in a child simulating a prolactin-secreting adenoma.

Authors:  Crésio Alves; Ana Cláudia Alves
Journal:  Childs Nerv Syst       Date:  2008-08-09       Impact factor: 1.475

8.  Quality of life in women with microprolactinoma treated with dopamine agonists.

Authors:  Erika Cesar de Oliveira Naliato; Alice Helena Dutra Violante; Dayse Caldas; Adilson Lamounier Filho; Christiane Rezende Loureiro; Rosita Fontes; Yolanda Schrank; Rodrigo Gomes de Souza; Mario Vaisman; Ermelinda Guerra; Arantzazu Sebastian; Annamaria Colao
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

9.  Importance of cannulated prolactin test in the definition of hyperprolactinaemia.

Authors:  M B Whyte; S Pramodh; L Srikugan; J A Gilbert; J P Miell; R A Sherwood; A M McGregor; S J B Aylwin
Journal:  Pituitary       Date:  2015-06       Impact factor: 4.107

10.  The influence of phytotherapy on macroprolactinoma size.

Authors:  Ivo Trogrlić; Dragan Trogrlić; Zoran Trogrlić
Journal:  Afr J Tradit Complement Altern Med       Date:  2011-12-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.